- Home
- CGON vs CMPO Comparison
CGON vs CMPO Comparison
Compare CGON & CMPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGON
- CMPO
- Stock Information
- Founded
- CGON 2010
- CMPO 2000
- Country
- CGON United States
- CMPO United States
- Employees
- CGON N/A
- CMPO N/A
- Industry
- CGON
- CMPO Finance: Consumer Services
- Sector
- CGON
- CMPO Finance
- Exchange
- CGON NYSE
- CMPO Nasdaq
- Market Cap
- CGON 1.3B
- CMPO 1.1B
- IPO Year
- CGON 2024
- CMPO N/A
- Fundamental
- Price
- CGON $24.13
- CMPO $11.56
- Analyst Decision
- CGON Strong Buy
- CMPO Strong Buy
- Analyst Count
- CGON 11
- CMPO 8
- Target Price
- CGON $62.90
- CMPO $16.19
- AVG Volume (30 Days)
- CGON 2.0M
- CMPO 554.6K
- Earning Date
- CGON 05-16-2025
- CMPO 05-12-2025
- Dividend Yield
- CGON N/A
- CMPO 2.21%
- EPS Growth
- CGON N/A
- CMPO N/A
- EPS
- CGON N/A
- CMPO N/A
- Revenue
- CGON $1,139,000.00
- CMPO $420,571,000.00
- Revenue This Year
- CGON N/A
- CMPO $7.26
- Revenue Next Year
- CGON $16,237.24
- CMPO $8.20
- P/E Ratio
- CGON N/A
- CMPO N/A
- Revenue Growth
- CGON 461.08
- CMPO 7.67
- 52 Week Low
- CGON $14.80
- CMPO $4.97
- 52 Week High
- CGON $40.47
- CMPO $14.71
- Technical
- Relative Strength Index (RSI)
- CGON 51.00
- CMPO 60.86
- Support Level
- CGON $21.00
- CMPO $10.82
- Resistance Level
- CGON $30.23
- CMPO $11.53
- Average True Range (ATR)
- CGON 2.31
- CMPO 0.32
- MACD
- CGON 0.16
- CMPO 0.11
- Stochastic Oscillator
- CGON 34.09
- CMPO 95.27
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
About CMPO CompoSecure Inc.
CompoSecure Inc is engaged in designing and manufacturing premium financial cards. The Company's metal payment card technology and Arculus security and authentication capabilities deliver premium branded experiences which enable people to access and use their assets, and ensure trust at the point of a transaction. Its products include Metal Cards and Arculus, a digital security platform. It has two reportable segments: Payment Card and Arculus.